Proteinea Revenue and Competitors
Estimated Revenue & Valuation
- Proteinea's estimated annual revenue is currently $10.2M per year.
- Proteinea's estimated revenue per employee is $193,019
Employee Data
- Proteinea has 53 Employees.
- Proteinea grew their employee count by -2% last year.
Proteinea's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | Structural Bioinformatics Researcher | Reveal Email/Phone |
3 | Research & Development Engineer @ PROGROW | Reveal Email/Phone |
Proteinea Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $79.1M | 417 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 20% | N/A | N/A |
#3 | $1.9M | 9 | -10% | N/A | N/A |
#4 | N/A | 7 | 0% | N/A | N/A |
#5 | $5.4M | 35 | 21% | N/A | N/A |
#6 | $0.8M | 4 | 0% | N/A | N/A |
#7 | $8.7M | 56 | 24% | N/A | N/A |
#8 | $1.4M | 8 | 14% | N/A | N/A |
#9 | $1.1M | 7 | 17% | N/A | N/A |
#10 | $36M | 232 | 19% | N/A | N/A |
What Is Proteinea?
Proteinea is an insect-based biotechnology startup based in Egypt/US. We are replacing the single-cell technologies with an insect-based production platform as a next-gen bio-manufacturing platform. We are turning the mass-reared insect larvae into mini-biofactories to produce recombinant proteins on a scale at a lower cost, reducing the capital and operational costs of conventional bioreactors.
keywords:N/AN/A
Total Funding
53
Number of Employees
$10.2M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Proteinea News
2022-04-13 - Top 5 Latest Biotechnological Discoveries in 2022 | by Alex ...
Proteinea, a US start-up makes recombinant easier by using insects' larvae as mini bioreactors. Bioprinting. When it comes to printing, you must...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.9M | 53 | 26% | N/A |
#2 | $18.7M | 53 | 8% | N/A |
#3 | $7.5M | 54 | 2% | N/A |
#4 | $9.8M | 54 | 38% | N/A |
#5 | $13.9M | 56 | 19% | N/A |